In the total cohort of 193 patients, high CEBPA PM was correlated with better treatment response and in a subcohort of 25 CN-AML patients without CEBPA and NPM1 mutations, cases with high CEBPA PM had longer overall survival (OS) compared to cases with low CEBPA PM. The gene discussed is CEBPA; the disease is acute myeloid leukemia.